-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Nanjing Chenruisheng research and development of V-9-M cholecystokinin nonapeptide project officially launched Semaglutide is a glucagon-like peptide receptor agonist, namely GLP-1 receptor agonist, human GLP-1 is produced by intestinal tract A peptide hormone secreted by tract L cells
.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) class of hypoglycemic drugs, which increase insulin secretion in a glucose-dependent manner and inhibit glucagon secretion , and can promote gastric emptying, centrally suppress appetite, reduce food intake, and then reduce glucose absorption to achieve the effect of lowering blood sugar
.
Its mechanism of action is to act on islet beta cells, promote the synthesis and secretion of insulin, stimulate the proliferation and differentiation of islet beta cells, inhibit the apoptosis of islet beta cells, increase the number of islet beta cells, and protect islet function
.
It can also act on islet alpha cells, inhibit the release of glucagon, and reduce the release of hepatic glucose
.
Acts on islet delta cells, promotes the secretion of somatostatin, and participates in the inhibition of glucagon secretion
.
Enhance insulin sensitivity, slow down gastric emptying, act on the hypothalamus to suppress appetite, reduce body weight, and achieve the effect of lowering blood sugar through these effects
.
Liraglutide acetate: Liraglutide is a clear, colorless solution
.
The dosage form is subcutaneous injection
.
After more than 10 years of research and development, liraglutide has many effects such as promoting islet cell regeneration, lowering blood sugar, reducing weight and protecting the cardiovascular system.
As a supplement to diet control and physical activity
.
Liraglutide is an acylated human glucagon-like peptide-1 (GLP-1) receptor agonist with 97% amino acid sequence homology to human endogenous GLP-1 (7-37), retaining It has all the biological activities of GLP-1 and has GLP-1 receptor agonism
.
Through the expression of recombinant DNA in Saccharomyces cerevisiae, its molecular structure has only one amino acid difference from the natural GLP-1 molecule.
The structure only modifies GLP-1 in the following two parts: that is, the 34th lysine is replaced by arginine.
Acid substitution, additionally adding a glutamate-mediated 16-carbon palmitoyl fatty acid side chain at lysine 26
.
Liraglutide is a human GLP-1 (glucagon-like peptide-1) analog that has been widely used in Europe, the United States, and Japan
.
GLP-1 is an incretin that promotes insulin secretion when ingesting nutrients orally, but human GLP-1 can be blocked by dipeptidyl peptidase -4 (DPP-4) degrades rapidly
.
Liraglutide is a full agonist of the GLP-1 receptor, and its amino acid sequence is 97% identical to that of human GLP-1
.
Structurally, there are only two differences between the two molecules.
First, the C16 fatty acid is linked to lysine through glutamic acid at position 26
.
Second, lysine was replaced by arginine at position 34 to ensure that the C16 side chain could only bind at position 26
.
The fatty acid side chain can reversibly bind liraglutide to albumin in the blood, prolong the action time of liraglutide, and enhance the resistance to DPP-4 enzymatic degradation.
Peptide molecules self-crosslink into heptamers at the injection site, thereby delaying their subcutaneous attraction, making their action time up to nearly 24 hours, and can be injected once a day and at any time, regardless of meals
.
Liraglutide is a revolutionary drug in the field of type 2 diabetes treatment.
It is suitable for type 2 diabetes patients whose blood sugar is still poorly controlled after treatment with metformin or sulfonylureas at high tolerable doses.
It is regulated in a glucose concentration-dependent manner.
Blood sugar, directly protects B cells, increases insulin secretion and reduces inappropriate glucagon secretion from alpha cells, reduces body weight by increasing satiety and reduces caloric intake, and lowers systolic blood pressure, the earlier the better
.
Liraglutide in combination with metformin or sulfonylureas has significant efficacy and few adverse reactions
.
.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) class of hypoglycemic drugs, which increase insulin secretion in a glucose-dependent manner and inhibit glucagon secretion , and can promote gastric emptying, centrally suppress appetite, reduce food intake, and then reduce glucose absorption to achieve the effect of lowering blood sugar
.
Its mechanism of action is to act on islet beta cells, promote the synthesis and secretion of insulin, stimulate the proliferation and differentiation of islet beta cells, inhibit the apoptosis of islet beta cells, increase the number of islet beta cells, and protect islet function
.
It can also act on islet alpha cells, inhibit the release of glucagon, and reduce the release of hepatic glucose
.
Acts on islet delta cells, promotes the secretion of somatostatin, and participates in the inhibition of glucagon secretion
.
Enhance insulin sensitivity, slow down gastric emptying, act on the hypothalamus to suppress appetite, reduce body weight, and achieve the effect of lowering blood sugar through these effects
.
Liraglutide acetate: Liraglutide is a clear, colorless solution
.
The dosage form is subcutaneous injection
.
After more than 10 years of research and development, liraglutide has many effects such as promoting islet cell regeneration, lowering blood sugar, reducing weight and protecting the cardiovascular system.
As a supplement to diet control and physical activity
.
Liraglutide is an acylated human glucagon-like peptide-1 (GLP-1) receptor agonist with 97% amino acid sequence homology to human endogenous GLP-1 (7-37), retaining It has all the biological activities of GLP-1 and has GLP-1 receptor agonism
.
Through the expression of recombinant DNA in Saccharomyces cerevisiae, its molecular structure has only one amino acid difference from the natural GLP-1 molecule.
The structure only modifies GLP-1 in the following two parts: that is, the 34th lysine is replaced by arginine.
Acid substitution, additionally adding a glutamate-mediated 16-carbon palmitoyl fatty acid side chain at lysine 26
.
Liraglutide is a human GLP-1 (glucagon-like peptide-1) analog that has been widely used in Europe, the United States, and Japan
.
GLP-1 is an incretin that promotes insulin secretion when ingesting nutrients orally, but human GLP-1 can be blocked by dipeptidyl peptidase -4 (DPP-4) degrades rapidly
.
Liraglutide is a full agonist of the GLP-1 receptor, and its amino acid sequence is 97% identical to that of human GLP-1
.
Structurally, there are only two differences between the two molecules.
First, the C16 fatty acid is linked to lysine through glutamic acid at position 26
.
Second, lysine was replaced by arginine at position 34 to ensure that the C16 side chain could only bind at position 26
.
The fatty acid side chain can reversibly bind liraglutide to albumin in the blood, prolong the action time of liraglutide, and enhance the resistance to DPP-4 enzymatic degradation.
Peptide molecules self-crosslink into heptamers at the injection site, thereby delaying their subcutaneous attraction, making their action time up to nearly 24 hours, and can be injected once a day and at any time, regardless of meals
.
Liraglutide is a revolutionary drug in the field of type 2 diabetes treatment.
It is suitable for type 2 diabetes patients whose blood sugar is still poorly controlled after treatment with metformin or sulfonylureas at high tolerable doses.
It is regulated in a glucose concentration-dependent manner.
Blood sugar, directly protects B cells, increases insulin secretion and reduces inappropriate glucagon secretion from alpha cells, reduces body weight by increasing satiety and reduces caloric intake, and lowers systolic blood pressure, the earlier the better
.
Liraglutide in combination with metformin or sulfonylureas has significant efficacy and few adverse reactions
.
